Marcum Wealth LLC reduced its position in shares of AstraZeneca PLC (NASDAQ:AZN – Free Report) by 5.2% in the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 8,875 shares of the company’s stock after selling 488 shares during the period. Marcum Wealth LLC’s holdings in AstraZeneca were worth $692,000 at the end of the most recent quarter.
Several other institutional investors and hedge funds also recently modified their holdings of the company. Able Wealth Management LLC acquired a new position in AstraZeneca during the fourth quarter valued at approximately $27,000. Pathway Financial Advisers LLC bought a new stake in AstraZeneca in the first quarter valued at approximately $29,000. Pin Oak Investment Advisors Inc. raised its stake in AstraZeneca by 468.4% in the fourth quarter. Pin Oak Investment Advisors Inc. now owns 449 shares of the company’s stock valued at $30,000 after buying an additional 370 shares during the period. RFP Financial Group LLC raised its stake in AstraZeneca by 56.3% in the first quarter. RFP Financial Group LLC now owns 494 shares of the company’s stock valued at $33,000 after buying an additional 178 shares during the period. Finally, Northwest Financial Advisors bought a new stake in AstraZeneca in the fourth quarter valued at approximately $34,000. 20.35% of the stock is owned by institutional investors and hedge funds.
AstraZeneca Price Performance
NASDAQ:AZN traded down $2.48 during trading hours on Monday, hitting $79.33. 5,728,821 shares of the company’s stock traded hands, compared to its average volume of 5,368,322. The firm has a market cap of $245.97 billion, a P/E ratio of 39.05, a P/E/G ratio of 1.55 and a beta of 0.45. AstraZeneca PLC has a 52 week low of $60.47 and a 52 week high of $82.01. The business’s fifty day simple moving average is $78.68 and its two-hundred day simple moving average is $72.36. The company has a quick ratio of 0.69, a current ratio of 0.89 and a debt-to-equity ratio of 0.69.
AstraZeneca Cuts Dividend
The business also recently disclosed a Semi-Annual dividend, which will be paid on Monday, September 9th. Investors of record on Friday, August 9th will be given a dividend of $0.49 per share. This represents a yield of 1.8%. The ex-dividend date of this dividend is Friday, August 9th. AstraZeneca’s dividend payout ratio (DPR) is presently 94.61%.
Analysts Set New Price Targets
A number of equities analysts have recently weighed in on the company. Argus increased their target price on AstraZeneca from $80.00 to $85.00 and gave the stock a “buy” rating in a research note on Thursday, May 30th. BMO Capital Markets raised their price objective on AstraZeneca from $80.00 to $82.00 and gave the stock an “outperform” rating in a research note on Friday, April 26th. Deutsche Bank Aktiengesellschaft upgraded AstraZeneca from a “sell” rating to a “hold” rating in a research note on Tuesday, April 16th. The Goldman Sachs Group started coverage on AstraZeneca in a research note on Thursday, May 30th. They set a “buy” rating and a $97.00 price objective on the stock. Finally, Citigroup raised AstraZeneca to a “strong-buy” rating in a report on Monday, June 24th. Three investment analysts have rated the stock with a hold rating, five have assigned a buy rating and three have given a strong buy rating to the company. According to data from MarketBeat.com, AstraZeneca currently has an average rating of “Buy” and an average price target of $88.00.
View Our Latest Analysis on AstraZeneca
AstraZeneca Profile
AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company's marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.
Recommended Stories
- Five stocks we like better than AstraZeneca
- Dividend Payout Ratio Calculator
- From Tokyo to Wall Street: Japan’s Market Impact on U.S. Stocks
- Why Special Dividends Can be a Delightful Surprise for Income Investors
- Arm Holdings: Does the 42% Drop Signal an AI Buying Opportunity?
- What is the Euro STOXX 50 Index?
- Texas Roadhouse Stampedes On EPS Beat as Comp Sales Surge 9.3%
Want to see what other hedge funds are holding AZN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for AstraZeneca PLC (NASDAQ:AZN – Free Report).
Receive News & Ratings for AstraZeneca Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca and related companies with MarketBeat.com's FREE daily email newsletter.